US Broker Ratings

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Unpacking a 66% Potential Upside with Strong Buy Ratings

Relay Therapeutics, Inc. (NASDAQ: RLAY), a clinical-stage precision medicines company, is capturing investor attention with its notable potential upside and unanimous buy ratings from analysts. Specializing in targeted oncology and..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Exploring a Promising 58.72% Upside Potential

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) stands out in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With a market capitalization of $1.55 billion, this Cambridge, Massachusetts-based..

Immatics N.V. (IMTX) Investor Outlook: Exploring a 93% Potential Upside in the Biotech Sector

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, is capturing investor attention with its promising position in the dynamic biotechnology industry. Specializing in T cell redirecting..

Definitive Healthcare Corp. (DH) Stock Analysis: Exploring a Potential 177% Upside

Definitive Healthcare Corp. (NASDAQ: DH) presents a compelling opportunity for investors seeking potential high returns in the healthcare sector. Despite its current challenges, the company’s strategic position in the health..

Arvinas, Inc. (ARVN) Stock Analysis: Exploring a 30% Upside Potential in Biotechnology

Arvinas, Inc. (NASDAQ: ARVN) is making waves in the biotechnology sector with its innovative approach to drug development, focusing on the degradation of disease-causing proteins. As a clinical-stage biotechnology company,..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Evaluating the Upside in a Specialty Drug Innovator

Phibro Animal Health Corporation (NASDAQ: PAHC) stands as a significant player in the healthcare sector, specifically within the drug manufacturing industry focusing on specialty and generic products. With a market..

Keros Therapeutics, Inc. (KROS) Stock Analysis: Uncovering a 102.98% Potential Upside in Biotech

Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company, is attracting significant attention in the biotechnology industry with its promising pipeline and remarkable potential upside. Situated in the dynamic healthcare..

Cogent Biosciences, Inc. (COGT) Stock Analysis: Strong Buy Ratings and a 56.51% Upside Potential

Cogent Biosciences, Inc. (NASDAQ: COGT) is garnering significant attention in the biotechnology sector, with a market capitalization of $5.62 billion. As a clinical-stage biotechnology company, Cogent focuses on developing precision..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Exploring a 56% Potential Upside in the Healthcare Sector

Fulgent Genetics, Inc. (NASDAQ: FLGT), a prominent player in the healthcare sector, is drawing investor attention with a significant potential upside of 56.38%. With its focus on diagnostics and research,..

Kura Oncology, Inc. (KURA) Stock Analysis: A Biotech with a Potential 282.83% Upside

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company based in San Diego, is making waves in the biotechnology industry with its innovative approach to cancer treatment. With a market..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Unveiling a Biotech Gem with 231.87% Potential Upside

Bicycle Therapeutics plc (NASDAQ: BCYC) emerges as a captivating prospect for investors seeking opportunities in the rapidly evolving biotechnology sector. With a market cap of $315.62 million, this UK-based clinical-stage..

AnaptysBio, Inc. (ANAB) Stock Analysis: Tapping into a 20.91% Potential Upside in the Biotech Sector

As the world continues to focus on innovative healthcare solutions, AnaptysBio, Inc. (NASDAQ: ANAB) stands out as an intriguing prospect in the biotechnology industry. With a market capitalization of $1.86..

Immunome, Inc. (IMNM) Stock Analysis: Biotech Innovator with 70% Upside Potential

Immunome, Inc. (NASDAQ: IMNM) has captured the attention of the investment community with its compelling growth narrative in the healthcare sector. Specializing in biotechnology, this U.S.-based company is at the..

Savara, Inc. (SVRA) Stock Analysis: A 109% Potential Upside Ignites Investor Interest

For investors with a keen eye on the biotechnology sector, Savara, Inc. (NASDAQ: SVRA) presents a compelling opportunity. With a market capitalization of $1.06 billion, this Langhorne, Pennsylvania-based company is..

Simulations Plus, Inc. (SLP) Stock Analysis: Navigating a 110% Potential Upside in Health Information Services

Simulations Plus, Inc. (SLP), a prominent player in the healthcare sector specializing in health information services, is capturing investor attention with its innovative suite of drug discovery and development software...

Avadel Pharmaceuticals plc (AVDL) Stock Analysis: Navigating the 54.90% Revenue Growth Amid Analyst Skepticism

Avadel Pharmaceuticals plc (NASDAQ: AVDL) has captured investor attention with its impressive 54.90% revenue growth. As a biopharmaceutical company headquartered in Dublin, Ireland, Avadel focuses on developing innovative treatments, notably..

Nutex Health Inc. (NUTX) Stock Analysis: Evaluating a 134% Potential Upside in the Healthcare Sector

Investors looking for opportunities in the healthcare sector might want to turn their attention to Nutex Health Inc. (NUTX), a company with a unique business model and a significant potential..

Akso Health Group (AHG) Stock Report: Navigating Challenges in the Medical Distribution Sector

Akso Health Group (NASDAQ: AHG), a key player in the medical distribution industry based in Qingdao, China, operates within the dynamic healthcare sector. With a market capitalization of $2.07 billion,..

Weave Communications, Inc. (WEAV): Investor Outlook Highlights an 83% Potential Upside

Weave Communications, Inc. (NASDAQ: WEAV), a key player in the healthcare sector, specifically in health information services, has garnered significant attention from investors due to its robust growth potential. Headquartered..

LENZ Therapeutics (LENZ): Investor Outlook on a Biotech Stock with a 346% Potential Upside

For investors eyeing opportunities in the healthcare sector, LENZ Therapeutics, Inc. (NASDAQ: LENZ) stands out with its compelling potential upside of 346.35%. Specializing in biopharmaceutical innovations aimed at improving vision,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds